MedTrace Logo

Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid Alcoholism

NCT00338598 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2018-01-17

Study results available
· View outcomes & findings →

Summary

This placebo-controlled study is designed to evaluate the efficacy of glycine, an agonist of the glycine-B co-agonist site of the NMDA receptor, on alcohol consumption and craving as well as negative symptoms in schizophrenia.

Glycine will decrease the rewarding action of ethanol and reduce ethanol consumption. Also, glycine will improve negative symptoms and cognitive deficits in schizophrenia.

Conditions

Interventions

DRUG

Glycine

Glycine, 0.8 gr per kg given in two daily doses

DRUG

placebo

Sponsors & Collaborators

  • Stanley Medical Research Institute

    collaborator OTHER

  • Yale University

    lead OTHER

Principal Investigators

  • Ismene Petrakis, M.D. · Yale University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-06-30
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00338598 on ClinicalTrials.gov